tbuckley/cabot-search huggingface dataset:
Early Release of Research Results
Authors: Suzanne W. Fletcher, Robert H. Fletcher
Journal: Annals of Internal Medicine (1991)

Editorials15 April 1991Early Release of Research ResultsSuzanne W. Fletcher, MD, Robert H. Fletcher, MDSuzanne W. Fletcher, MDSearch for more papers by this author, Robert H. Fletcher, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-8-698 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHistorically, medical research reported in peer-reviewed journals all too often has been thought to be the dry, obtuse, somewhat boring stuff of medical science, tough even for dedicated physicians to digest. Times have changed. Medical research news is now eagerly sought by the lay press and public; medical headlines are seen and heard daily. Patient groups, especially the articulate, politically sophisticated sufferers of the acquired immunodeficiency syndrome (AIDS), want medical news as fast as possible, in the desperate hope that lives can be saved.Researchers are having the fruits of years of labor publicly acclaimed. To be quoted in a...References1. Okie S. Medical journals: slowing flow of news on life-saving discoveries? The Washington Post. 21 Jan 1991, A19. Google Scholar2. Relman A. More on the Ingelfinger rule. N Engl J Med. 1988;318: 1125-6. CrossrefMedlineGoogle Scholar3. LundbergGlassJoyce GRL. Policy of AMA journals regarding release of information to the public. JAMA. 1991;265:400. CrossrefMedlineGoogle Scholar4. Information for authors. Ann Intern Med. 1991; 114:1-9-12. LinkGoogle Scholar5. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991;265:391-5. CrossrefMedlineGoogle Scholar6. RolandKirkpatrick CR. Time lapse between hypothesis and publication in the medical sciences. N Engl J Med. 1975;292:1273-6. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByMass media release of medical research resultsEthical Issues Related to Clinical Pharmacy Research (ACCP)Ethical Issues Related to Clinical Pharmacy Research (ACCP)Reply to Dr. Ellen BurgessMedical journals and society: threats and responsibilitiesOn Clinical AlertsVincent T. DeVita Jr., MD 15 April 1991Volume 114, Issue 8Page: 698-700KeywordsAIDSResearch reporting guidelines Issue Published: 15 April 1991 PDF DownloadLoading ...
Metabolism and placental transfer of 125I-proinsulin and 125I-tyrosylated C-peptide in the pregnant rhesus monkey.
Authors: P A Gruppuso, J B Susa, P Sehgal, B Frank, R Schwartz
Journal: Journal of Clinical Investigation (1987)

125I-Proinsulin or 125I-tyrosylated-C-peptide (125I-tyr-CP) was administered to pregnant Rhesus monkeys by bolus followed by constant infusion to examine placental transfer of these peptides. At the end of each infusion, fetuses were exsanguinated in situ via the umbilical vein. The bolus-constant infusion technique produced a steady state in maternal plasma of immunoprecipitable label, measured using excess insulin or C-peptide antiserum. In animals infused with 125I-proinsulin, analysis of umbilical venous plasma revealed no apparent transfer to the fetus of immunoprecipitable label. In animals infused with 125I-tyr-CP, 3-13% of the umbilical venous plasma radioactivity was immunoprecipitable, representing 1.4-5.8% of the immunoprecipitable radioactivity in maternal plasma at delivery. Gel filtration chromatography of umbilical venous plasma revealed that the immunoprecipitated moiety was a fragment of 125I-tyr-CP. Analysis of maternal plasma showed that the predominant peak of radioactivity represented intact C-peptide. A peak corresponding to the fetal immunoprecipitable peak was also present. Analysis of simultaneous maternal arterial and uterine vein plasma samples showed that degradation of 125I-tyr-CP occurred across the uterus. Studies in one nonpregnant and three postpartum animals indicated that pregnancy increased the rate of metabolism of 125I-tyr-CP. When 125I-tyr-CP was incubated with trophoblastic cells in culture, degradation to a species corresponding on gel filtration to the immunoprecipitable fetal metabolite was found. We conclude that proinsulin, like insulin, does not traverse the placenta. Immunoreactive fragments of C-peptide do cross, however, and pregnancy alters the metabolism of 125I-tyr-CP, probably owing to placental degradation.
The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons
Authors: Andreas Leffler, Michael J. Fischer, Dietlinde Rehner, Stephanie Kienel, Katrin Kistner, Susanne K. Sauer, Narender R. Gavva, Peter W. Reeh, Carla Nau
Journal: Journal of Clinical Investigation (2008)

Local anesthetics (LAs) block the generation and propagation of action potentials by interacting with specific sites of voltage-gated Na+ channels. LAs can also excite sensory neurons and be neurotoxic through mechanisms that are as yet undefined. Nonspecific cation channels of the transient receptor potential (TRP) channel family that are predominantly expressed by nociceptive sensory neurons render these neurons sensitive to a variety of insults. Here we demonstrated that the LA lidocaine activated TRP channel family receptors TRPV1 and, to a lesser extent, TRPA1 in rodent dorsal root ganglion sensory neurons as well as in HEK293t cells expressing TRPV1 or TRPA1. Lidocaine also induced a TRPV1-dependent release of calcitonin gene–related peptide (CGRP) from isolated skin and peripheral nerve. Lidocaine sensitivity of TRPV1 required segments of the putative vanilloid-binding domain within and adjacent to transmembrane domain 3, was diminished under phosphatidylinositol 4,5-bisphosphate depletion, and was abrogated by a point mutation at residue R701 in the proximal C-terminal TRP domain. These data identify TRPV1 and TRPA1 as putative key elements of LA-induced nociceptor excitation. This effect is sufficient to release CGRP, a key component of neurogenic inflammation, and warrants investigation into the role of TRPV1 and TRPA1 in LA-induced neurotoxicity.
Detection of specific IgE antibodies in the sera of patients allergic to birch pollen using recombinant allergens Bet v 1, Bet v 2, Bet v 4: evaluation of different IgE reactivity profiles
Authors: R. E. Rossi, G. Monasterolo, S. Monasterolo
Journal: Allergy (2003)

Birch pollen is a significant cause of immediate hypersensitivity among susceptible subjects in temperate climates, affecting 5-54% of the population in western Europe. We examined the specific serum IgE antibodies towards recombinant allergens Bet v 1, Bet v 2 and Bet v 4 in birch-sensitive patients from the province of Cuneo, north-west Italy.Sera were obtained from 372 patients with symptomatic birch pollen-induced allergic rhinitis and/or asthma. A subgroup of these patients suffered from oral allergy syndrome after eating apple. Their sera were evaluated for specific IgE against natural birch pollen and apple extract, as well as Bet v 1, Bet v 2 and Bet v 4 using Pharmacia CAP system (Pharmacia, Uppsala, Sweden).Of 372 patients 215 (57.80%) had serum-specific IgE towards Bet v 1. A total of 166 sera (44.62%) contained serum-specific IgE to Bet v 2, while Bet v 4 IgE reactivity was documented in 35 subjects (9.41%). Moreover, 146 (39.25%) patients were monosensitized to Bet v 1; 96 (25.81%) patients were monosensitized to Bet v 2; only four sera (1.08%) contained specific IgE towards Bet v 4. Thirty-nine sera (11.02%) did not contain specific IgE to these individual birch pollen allergens. Of course, all 372 sera (100%) had specific IgE against natural birch pollen extract, of which 162 (43.55%) contained specific IgE to apple extract (75.35% of Bet v 1 positive sera).In this study we observed that three birch pollen recombinant allergens alone, could sufficiently identify 90% of birch pollen-sensitive patients. Therefore, for a more precise IgE profile of patients allergic to birch, further purified birch pollen allergens (i.e. Bet v 6, Bet v 7, Bet v 8) will be required.
Dual publication of surgical abstracts is acceptable
Authors: J J Earnshaw, J R Farndon, P J Guillou, C D Johnson, J A Murie
Journal: BMJ (1997)

Editor—I C Cameron and colleagues raise two important issues: whether surgeons wish to see duplicate presentations of research at national meetings and whether dual publication of abstracts should be prevented.1 The British Journal of Surgery has published abstracts for the Association of Surgeons of Great Britain and Ireland, a general surgical meeting, since 1996. The proceedings of the Vascular Surgical Society of Great Britain and Ireland are also published (59 abstracts from the …
Hyperkalemia in Hospitalized Patients Treated with Trimethoprim-Sulfamethoxazole
Authors: Rajendran Alappan
Journal: Annals of Internal Medicine (1996)

Objective: To determine the effect of standard-dose trimethoprim-sulfamethoxazole on serum potassium concentration in hospitalized patients. Design: Prospective chart review. Setting: Community-based teaching hospital. Patients: 105 patients with various infections were hospitalized and treated. Eighty patients treated with standard-dose trimethoprim-sulfamethoxazole (trimethoprim, less than equals 320 mg/d; sulfamethoxazole, less than equals 1600 mg/d) composed the treatment group; 25 patients treated with other antibiotic agents served as the control group. Measurements: Serum sodium, potassium, and chloride concentrations; serum carbon dioxide content; anion gap; blood urea nitrogen level; and serum creatinine level. Results: The serum potassium concentration in the treatment group (mean ±SD) was 3.89 ± 0.46 mmol/L (95% CI, 3.79 to 3.99 mmol/L), and it increased by 1.21 mmol/L (CI, 1.09 to 1.32 mmol/L) 4.6 ± 2.2 days after trimethoprim-sulfamethoxazole therapy was initiated. Blood urea nitrogen levels increased from 7.92 ± 5.7 mmol/L (CI, 6.67 to 9.16 mmol/L) to 9.2 ± 5.8 mmol/L (CI, 7.9 to 10.5 mmol/L), and serum creatinine levels increased from 102.5 ± 49.5 µmol/L (CI, 91.4 to 113.6 µmol/L) to 126.1 ± 70.7 µmol/L (CI, 110.3 to 141.9 µmol/L). Patients with a serum creatinine level of 106 µmol/L (1.2 mg/dL) or more developed a higher peak potassium concentration (5.37 ± 0.59 mmol/L [CI, 5.15 to 5.59 mmol/L]) than patients with a serum creatinine level of less than 106 µmol/L (4.95 ± 0.48 mmol/L [CI, 4.80 to 5.08 mmol/L]). Patients with diabetes had a slightly higher peak potassium concentration (5.14 ± 0.45 mmol/L [CI, 4.93 to 5.35 mmol/L]) than did patients without diabetes (5.08 ± 0.59 mmol/L [CI, 4.93 to 5.23 mmol/L]), but the difference was not statistically significant. The serum potassium concentration in the control group was 4.33 ± 0.45 mmol/L (CI, 4.15 to 4.51 mmol/L), and it decreased nonsignificantly over 5 days of therapy. Conclusions: Standard-dose trimethoprim-sulfamethoxazole therapy used to treat various infections leads to an increase in serum potassium concentration. A peak serum potassium concentration greater than 5.0 mmol/L developed in 62.5% of patients; severe hyperkalemia (peak serum potassium concentration more than equals 5.5 mmol/L) occurred in 21.2% of patients. Patients treated with standard-dose trimethoprim-sulfamethoxazole should be monitored closely for the development of hyperkalemia, especially if they have concurrent renal insufficiency (serum creatinine level more than equals 106 µmol/L).
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
Authors: David T. Teachey, Susan R. Rheingold, Shannon L. Maude, Gerhard Zugmaier, David M. Barrett, Alix E. Seif, Kim E. Nichols, Erica K. Suppa, Michael Kalos, Robert A. Berg, Julie C. Fitzgerald, Richard Aplenc, Lia Gore, Stephan A. Grupp
Journal: Blood (2013)
KARTAGENER'S SYNDROME AND SCHIZOPHRENIA: A REPORT OF A CASE WITH CHROMOSOMAL STUDIES
Authors: IRA D. GLICK, DAVID N. GRAUBERT
Journal: American Journal of Psychiatry (1964)

This is the fourth reported case of Kartagener's syndrome occurring with a schizophrenic reaction. This patient, unlike a previously reported case, had an I.Q. in the very superior range. Chromosomal studies revealed an absence of any chromosomal abnormality.
Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector.
Authors: C E Walsh, A W Nienhuis, R J Samulski, M G Brown, J L Miller, N S Young, J M Liu
Journal: Journal of Clinical Investigation (1994)

Fanconi anemia (FA) is a recessive inherited disease charac- terized by defective DNA repair.FA cells are hypersensitive to DNA cross-linking agents that cause chromosomal insta- bility and cell death.FA is manifested clinically by progres- sive pancytopenia, variable physical anomalies, and predis- position to malignancy.Four complementation groups have been identified, termed A, B, C, and D. The gene for the FA complementation group C, FACC, has been cloned.Expres- sion of the FACC cDNA corrects the phenotypic defect of FA (C) cells, resulting in normalized cell growth in the pres- ence of DNA cross-linking agents such as mitomycin C (MMC).Gene transfer of the FACC gene should provide a survival advantage to transduced hematopoietic cells, sug- gesting that FA might be an ideal candidate for gene therapy.We demonstrated efficient transduction, expression, and phenotypic correction in lymphoblastoid cell lines de- rived from FA (C) patients using a recombinant adeno-asso- ciated virus (rAAV) vector containing the FACC gene.Mo- lecular characterization of the transduced FACC gene showed an intact unrearranged proviral genome with ex- pression sufficient to normalize cell growth, cell cycle kinet- ics and chromosomal breakage in the presence of MMC.These observations were extended by testing rAAV trans- duction in hematopoietic progenitor cells.Peripheral blood CD34+ cells isolated from a FA(C) patient and transduced with rAAV/FACC virus yielded 5-10-fold more progenitor colonies than mock-infected cells, consistent with genetic "rescue" of corrected cells.This is the first demonstration of rAAV gene correction in primary human hematopoietic progenitor cells and has important implications for gene therapy of hematopoietic disorders, specifically FA. (
Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries
Authors: KA Boisen, M Kaleva, KM Main, HE Virtanen, A-M Haavisto, IM Schmidt, M Chellakooty, IN Damgaard, C Mau, M Reunanen, NE Skakkebaek, J Toppari
Journal: The Lancet (2004)
Erratum: Corrigendum: Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cells
Authors: Natalie A Hutnick, Diane G Carnathan, Sheri A Dubey, George Makedonas, Kara S Cox, Lisa Kierstead, Sarah J Ratcliffe, Michael N Robertson, Danilo R Casimiro, Hildegund C J Ertl, Michael R Betts
Journal: Nature Medicine (2009)
Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement
Authors: H A E M van Heereveld
Journal: Annals of the Rheumatic Diseases (2001)

The need for prevention of venous thromboembolism (VTE) after total hip or knee replacement is obvious. However, the optimal regimen to achieve this remains to be defined. In patients with rheumatoid arthritis (RA) long term coumarins may not be necessary owing to the use of non-steroidal anti-inflammatory drugs (NSAIDs). 103 patients in whom 151 surgical procedures were performed (55 hip and 96 knee prostheses) were treated only with short term subcutaneous heparin. NSAIDs were used daily in 85% of the patients, and they were continued after hospital discharge. Only one patient developed symptomatic deep venous thrombosis during one year follow up. Bleeding complications were seen in 20/151 (13%) of the surgical procedures, all clinically judged as minor, and recovery was not delayed except in one case. Short term (low molecular weight) heparin appears to be an adequate, simple, and safe method for prevention of symptomatic VTE in patients with RA after knee or hip replacement, though further studies are necessary to confirm these preliminary findings.
SOME INVESTIGATIONS ON THE VALUE OF CALCIFEROL THERAPY IN LUPUS VULGARIS
Authors: M. RUITER, H. D. GROEN
Journal: British Journal of Dermatology (1950)

Journal Article SOME INVESTIGATIONS ON THE VALUE OF CALCIFEROL THERAPY IN LUPUS VULGARIS Get access M. RUITER, M. RUITER Dermatological Clinic of the University of Groningen (Holland) Search for other works by this author on: Oxford Academic Google Scholar H. D. GROEN H. D. GROEN Dermatological Clinic of the University of Groningen (Holland) Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 62, Issue 1, 1 January 1950, Pages 15–19, https://doi.org/10.1111/j.1365-2133.1950.tb11108.x Published: 01 January 1950
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
Authors: Rikke B Holmgaard, Dmitriy Zamarin, David H Munn, Jedd D Wolchok, James P Allison
Journal: Journal for ImmunoTherapy of Cancer (2013)

Meeting abstracts The CTLA-4 blocking antibody ipilimumab results in durable responses in metastatic melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for identification of resistance mechanisms and development of combinatorial strategies. We examine the
Reconstitution of Coronary Blood Flow Using Autogenous Vein Bypass Grafts.
Authors: William L. Winters
Journal: Annals of Internal Medicine (1970)

Meeting Abstracts1 May 1970Reconstitution of Coronary Blood Flow Using Autogenous Vein Bypass Grafts.William L. Winters Jr., M.D., F.A.C.P., Paul K. Peterson, M.D., F.A.C.P., George C. Morris, M.D., Jimmy Howell, M.D., George Reul, M.D., H. Liston Beazley, M.D., F.A.C.P., Don W. Chapman, M.D., F.A.C.P.William L. Winters Jr., M.D., F.A.C.P.Search for more papers by this author, Paul K. Peterson, M.D., F.A.C.P.Search for more papers by this author, George C. Morris, M.D.Search for more papers by this author, Jimmy Howell, M.D.Search for more papers by this author, George Reul, M.D.Search for more papers by this author, H. Liston Beazley, M.D., F.A.C.P.Search for more papers by this author, Don W. Chapman, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-5-781_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOur group's extensive successful use of autogenous vein grafts in bypass and reconstruction of small arterial vessels in extremities prompted use of similar bypass grafts in the coronary circulation. The first 75 patients so treated are reported. There were 65 men and 10 women with ages ranging from 30 to 72 years. All experienced exertional angina, 50% with rest or nocturnal angina. All were under medical coronary programs with incomplete control of symptoms. Duration of symptoms ranged from 3 months to 6 years. One third had ECG evidence of a prior myocardial infarction. One third had elevated left ventricular end-diastolic... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Houston, Tex. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1970Volume 72, Issue 5Page: 781-781KeywordsAnginaBlood flowMyocardial infarctionVeins Issue Published: 1 May 1970 PDF DownloadLoading ...
Incidence and significance of abnormal signal-averaged ECGS as determined serially after myocardial infarction
Authors: Michael A. Graceffo, Andrew J. Boulet, Ann Walling, Tuhin K. Chaudhuri, Robert J. Chilton, Deborah A. Hauger, Robert A. O'Rourke
Journal: Journal of the American College of Cardiology (1991)
TCT-360 Is there a Different of Management for ST-Elevation Myocardial Infarction regarding Gender? Myth or Reality? Data from a Prospective Registry of 5000 Patients
Authors: Marc Bedossa, Guillaume Leurent, Isabelle Coudert, Philippe Druelles, Jean Philippe Hacot, Benoit Moquet, Dominique Boulmier, Herve le Breton
Journal: Journal of the American College of Cardiology (2012)
First stem cell bank in the world is opened in UK
Authors: Susan Mayor
Journal: BMJ (2004)

The first stem cell bank in the world opened last week in the United Kingdom, with the aim of providing an international resource for storing, characterising, and supplying ethically approved, quality controlled, stem cell lines for research and, ultimately, for treatment.

The bank is being run by the National Institute for Biological Standards and Control—a government funded organisation involved in quality assurance of research related to biological medicines.

Its key aims are to improve access to high …
Autoantibodies Present Before Symptom Onset in Primary Sjögren Syndrome
Authors: Roland Jonsson, Elke Theander, Bitte Sjöström, Karl Brokstad, Gunnel Henriksson
Journal: JAMA (2013)

Autoantibodies are characteristic of primary Sjögren syndrome1 and may be involved in its pathogenesis.2 We investigated autoantibodies present before symptom onset in patients with Sjögren syndrome because data on this issue are limited.
The burden of upper gastrointestinal endoscopy in patients with Barrett’s esophagus
Authors: M. Kruijshaar, M. Kerkhof, P. Siersema, E. Steyerberg, M. Homs, M-L. Essink-Bot
Journal: Endoscopy (2006)

Patients with Barrett's esophagus are recommended to undergo regular surveillance with upper gastrointestinal endoscopy, an invasive procedure that may cause anxiety, pain, and discomfort. We assessed to what extent patients perceived this procedure as burdensome.A total of 192 patients with Barrett's esophagus were asked to fill out questionnaires at 1 week and immediately before endoscopy, and at 1 week and 1 month afterwards. Four variables were assessed: (i) pain and discomfort experienced during endoscopy; (ii) symptoms; (iii) psychological burden, i. e., anxiety, depression and distress levels (Hospital Anxiety and Depression scale, Impact of Event Scale); and (iv) perceived risk of developing adenocarcinoma.At least one questionnaire was returned by 180 patients (94 %), 151 completed all four (79 %). Of all patients, only 14 % experienced the endoscopy as painful. However, 59 % reported it to be burdensome. Apart from an increase in throat ache (47 % after endoscopy versus 12 % before), the procedure did not cause physical symptoms. Patients' anxiety, depression, and distress levels were significantly increased in the week before endoscopy compared with the week after. Patients perceiving their risk of developing adenocarcinoma as high reported higher levels of psychological distress and that the procedure was a greater burden.Upper gastrointestinal endoscopy is burdensome for many patients with Barrett's esophagus and causes moderate distress. Perception of a high risk of adenocarcinoma may increase distress and the burden experienced from the procedure. The benefits of endoscopic surveillance for patients with Barrett's esophagus should be weighed against its drawbacks, including the short-term burden for patients.
ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography
Authors: Pamela S. Douglas, Mario J. Garcia, David E. Haines, Wyman W. Lai, Warren J. Manning, Ayan R. Patel, Michael H. Picard, Donna M. Polk, Michael Ragosta, R. Parker Ward, Rory B. Weiner, Steven R. Bailey, Peter Alagona, Jeffrey L. Anderson, Jeanne M. DeCara, Rowena J. Dolor, Reza Fazel, John A. Gillespie, Paul A. Heidenreich, Luci K. Leykum, Joseph E. Marine, Gregory J. Mishkel, Patricia A. Pellikka, Gilbert L. Raff, Krishnaswami Vijayaraghavan, Neil J. Weissman, Katherine C. Wu, Michael J. Wolk, Robert C. Hendel, Christopher M. Kramer, James K. Min, Manesh R. Patel, Leslee Shaw, Raymond F. Stainback, Joseph M. Allen
Journal: Journal of the American College of Cardiology (2011)